TMCnet News

Research and Markets: Diffuse Large B-Cell Lymphoma Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Diffuse Large B-Cell Lymphoma
[August 13, 2015]

Research and Markets: Diffuse Large B-Cell Lymphoma Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Diffuse Large B-Cell Lymphoma


Research and Markets (http://www.researchandmarkets.com/research/p7xnl2/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team.

Scope



  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies

Companies Mentioned


  • AbbVie Inc.
  • Affimed Therapeutics AG
  • Amgen Inc.
  • Aprogen, Inc.
  • Arrien Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Limited
  • Bayer AG
  • BIND Therapeutics, Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cell>Point, L.L.C.
  • Cellular Biomedicine Group, Inc.
  • Constellation Pharmaceuticals, Inc.
  • CTI (News - Alert) BioPharma Corp.
  • CureTech Ltd.
  • Curis, Inc.
  • Eisai Co., Ltd.
  • EpiZyme, Inc.
  • Erytech Pharma SA
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson

For more information visit http://www.researchandmarkets.com/research/p7xnl2/diffuse_large


[ Back To TMCnet.com's Homepage ]